Skip to main content

View full-text article in PMC

. 2018 Jan 15;10(1):31–39. doi: 10.4251/wjgo.v10.i1.31

Table 5.

Relationship between adjuvant treatment and the prognosis of T4bN1-3M0/TxN3bM0 gastric cancer patients

Treatment		n	Median DFS (mo)	3-yr DFS (%)	P value	Median OS (mo)	5-yr OS (%)	P value
Adjuvant chemotherapy	Yes	164	12.3	10.4%	0.000	25.7	16.1%	0.532
Adjuvant chemotherapy	No	12	2.8	0.0%		18.7	22.2%
Chemotherapy	Mono- therapy	10	6.7	0.0%	0.583	20.3	0.0%	0.661
Regimen	Doublet	134	12.0	5.3%		26.3	17.4%
Regimen	Triple	20	13.0	5.3%		29.7	18.5%
Adjuvant chemotherapy time	≥ 6 mo	39	23.2	20.2%	0.000	40.2	25.0%	0.001
Adjuvant chemotherapy time	< 6 mo	125	9.9	7.3%		21.6	13.4%

DFS: Disease-free survival.